Property based optimization of δ-lactam HDAC inhibitors for metabolic stability

Hong Chul Yoon, Eunhyun Choi, Jung Eun Park, Misun Cho, Jeong Jea Seo, Soo Jin Oh, Jong Soon Kang, Hwan Mook Kim, Song Kyu Park, Kiho Lee, Gyoonhee Han

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The novel δ-lactam based HDAC inhibitor, KBH-A118 (3) shows a good HDAC enzyme and cancer cell growth inhibitory activities but has undesirable pharmacokinetics profiles because of instability in mouse liver microsome. To improve metabolic stability, various analogues were prepared with substituents on aromatic ring of cap group and various chain lengths between the cap group and δ-lactam core. The newly prepared analogues showed moderate to potent in vitro activities. Among them six compounds (8a, 8e, 8j, 8n, 8t, and 8v) were evaluated on mouse liver microsome assay and it turned out that the microsomal stabilities were dependent on lipophilicity and the number of the rotatable bonds. Finally, the animal pharmacokinetic profiles of 8e displayed improving oral exposure and oral bioavailability.

Original languageEnglish
Pages (from-to)6808-6811
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume20
Issue number22
DOIs
Publication statusPublished - 2010 Nov 15

Fingerprint

Lactams
Histone Deacetylase Inhibitors
Liver Microsomes
Pharmacokinetics
Liver
Biological Availability
Cell growth
Chain length
Assays
Animals
Enzymes
Growth
Neoplasms
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Yoon, Hong Chul ; Choi, Eunhyun ; Park, Jung Eun ; Cho, Misun ; Seo, Jeong Jea ; Oh, Soo Jin ; Kang, Jong Soon ; Kim, Hwan Mook ; Park, Song Kyu ; Lee, Kiho ; Han, Gyoonhee. / Property based optimization of δ-lactam HDAC inhibitors for metabolic stability. In: Bioorganic and Medicinal Chemistry Letters. 2010 ; Vol. 20, No. 22. pp. 6808-6811.
@article{c5a69a059e8a44249204230ef5377ace,
title = "Property based optimization of δ-lactam HDAC inhibitors for metabolic stability",
abstract = "The novel δ-lactam based HDAC inhibitor, KBH-A118 (3) shows a good HDAC enzyme and cancer cell growth inhibitory activities but has undesirable pharmacokinetics profiles because of instability in mouse liver microsome. To improve metabolic stability, various analogues were prepared with substituents on aromatic ring of cap group and various chain lengths between the cap group and δ-lactam core. The newly prepared analogues showed moderate to potent in vitro activities. Among them six compounds (8a, 8e, 8j, 8n, 8t, and 8v) were evaluated on mouse liver microsome assay and it turned out that the microsomal stabilities were dependent on lipophilicity and the number of the rotatable bonds. Finally, the animal pharmacokinetic profiles of 8e displayed improving oral exposure and oral bioavailability.",
author = "Yoon, {Hong Chul} and Eunhyun Choi and Park, {Jung Eun} and Misun Cho and Seo, {Jeong Jea} and Oh, {Soo Jin} and Kang, {Jong Soon} and Kim, {Hwan Mook} and Park, {Song Kyu} and Kiho Lee and Gyoonhee Han",
year = "2010",
month = "11",
day = "15",
doi = "10.1016/j.bmcl.2010.08.117",
language = "English",
volume = "20",
pages = "6808--6811",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "22",

}

Yoon, HC, Choi, E, Park, JE, Cho, M, Seo, JJ, Oh, SJ, Kang, JS, Kim, HM, Park, SK, Lee, K & Han, G 2010, 'Property based optimization of δ-lactam HDAC inhibitors for metabolic stability', Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 22, pp. 6808-6811. https://doi.org/10.1016/j.bmcl.2010.08.117

Property based optimization of δ-lactam HDAC inhibitors for metabolic stability. / Yoon, Hong Chul; Choi, Eunhyun; Park, Jung Eun; Cho, Misun; Seo, Jeong Jea; Oh, Soo Jin; Kang, Jong Soon; Kim, Hwan Mook; Park, Song Kyu; Lee, Kiho; Han, Gyoonhee.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 20, No. 22, 15.11.2010, p. 6808-6811.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Property based optimization of δ-lactam HDAC inhibitors for metabolic stability

AU - Yoon, Hong Chul

AU - Choi, Eunhyun

AU - Park, Jung Eun

AU - Cho, Misun

AU - Seo, Jeong Jea

AU - Oh, Soo Jin

AU - Kang, Jong Soon

AU - Kim, Hwan Mook

AU - Park, Song Kyu

AU - Lee, Kiho

AU - Han, Gyoonhee

PY - 2010/11/15

Y1 - 2010/11/15

N2 - The novel δ-lactam based HDAC inhibitor, KBH-A118 (3) shows a good HDAC enzyme and cancer cell growth inhibitory activities but has undesirable pharmacokinetics profiles because of instability in mouse liver microsome. To improve metabolic stability, various analogues were prepared with substituents on aromatic ring of cap group and various chain lengths between the cap group and δ-lactam core. The newly prepared analogues showed moderate to potent in vitro activities. Among them six compounds (8a, 8e, 8j, 8n, 8t, and 8v) were evaluated on mouse liver microsome assay and it turned out that the microsomal stabilities were dependent on lipophilicity and the number of the rotatable bonds. Finally, the animal pharmacokinetic profiles of 8e displayed improving oral exposure and oral bioavailability.

AB - The novel δ-lactam based HDAC inhibitor, KBH-A118 (3) shows a good HDAC enzyme and cancer cell growth inhibitory activities but has undesirable pharmacokinetics profiles because of instability in mouse liver microsome. To improve metabolic stability, various analogues were prepared with substituents on aromatic ring of cap group and various chain lengths between the cap group and δ-lactam core. The newly prepared analogues showed moderate to potent in vitro activities. Among them six compounds (8a, 8e, 8j, 8n, 8t, and 8v) were evaluated on mouse liver microsome assay and it turned out that the microsomal stabilities were dependent on lipophilicity and the number of the rotatable bonds. Finally, the animal pharmacokinetic profiles of 8e displayed improving oral exposure and oral bioavailability.

UR - http://www.scopus.com/inward/record.url?scp=77958052585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958052585&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2010.08.117

DO - 10.1016/j.bmcl.2010.08.117

M3 - Article

VL - 20

SP - 6808

EP - 6811

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 22

ER -